These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25468795)

  • 21. Pharmacokinetic and pharmacodynamic modeling of sarafloxacin against avian pathogenic Escherichia coli in Muscovy ducks.
    Yu Y; Zhou YF; Sun J; Shi W; Liao XP; Liu YH
    BMC Vet Res; 2017 Feb; 13(1):47. PubMed ID: 28183350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. E. coli Resistance to Ciprofloxacin and Common Associated Factors.
    Jadoon RJ; Jalal-ud-Din M; Khan SA
    J Coll Physicians Surg Pak; 2015 Nov; 25(11):824-7. PubMed ID: 26577970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibacterial activity and synergistic effect between watercress extracts, 2-phenylethyl isothiocyanate and antibiotics against 11 isolates of Escherichia coli from clinical and animal source.
    Freitas E; Aires A; de Santos Rosa EA; Saavedra MJ
    Lett Appl Microbiol; 2013 Oct; 57(4):266-73. PubMed ID: 23682789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea.
    Lee MY; Choi HJ; Choi JY; Song M; Song Y; Kim SW; Chang HH; Jung SI; Kim YS; Ki HK; Son JS; Kwon KT; Heo ST; Yeom JS; Shin SY; Chung DR; Peck KR; Song JH; Ko KS
    J Infect; 2010 Feb; 60(2):146-53. PubMed ID: 19932131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo selection of an Escherichia coli isolate highly resistant to ciprofloxacin and ceftazidime: role of a 4-bp duplication in acrR and ampC overexpression.
    Corvec S; Lepelletier D; Reynaud A; Dauvergne S; Giraudeau C; Caroff N
    Int J Antimicrob Agents; 2008 Aug; 32(2):196-8. PubMed ID: 18571906
    [No Abstract]   [Full Text] [Related]  

  • 27. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
    Zhao X; Quinn B; Kerns R; Drlica K
    J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High percentage of resistance to ciprofloxacin and qnrB19 gene identified in urinary isolates of extended-spectrum beta-lactamase-producing Escherichia coli in Madrid, Spain.
    Ríos E; Rodríguez-Avial I; Rodríguez-Avial C; Hernandez E; Picazo JJ
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):380-3. PubMed ID: 20638608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contribution of QnrA, a Plasmid-Mediated Quinolone Resistance Peptide, to Survival of Escherichia coli Exposed to a Lethal Ciprofloxacin Concentration.
    Goto K; Kawamura K; Arakawa Y
    Jpn J Infect Dis; 2015; 68(3):196-202. PubMed ID: 25672356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rise in ciprofloxacin resistance in Escherichia coli from urinary tract infections from 1999-2004.
    Barisić Z; Borzić E; Kraljević KS; Carev M; Zoranić V; Kaliterna V
    Int J Antimicrob Agents; 2005 Jun; 25(6):550-1. PubMed ID: 15878822
    [No Abstract]   [Full Text] [Related]  

  • 31. High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea.
    Shin JH; Jung HJ; Lee JY; Kim HR; Lee JN; Chang CL
    Microb Drug Resist; 2008 Sep; 14(3):221-6. PubMed ID: 18707554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of subinhibitory concentrations of amikacin and ciprofloxacin on the hydrophobicity and adherence to epithelial cells of uropathogenic Escherichia coli strains.
    Wojnicz D; Jankowski S
    Int J Antimicrob Agents; 2007 Jun; 29(6):700-4. PubMed ID: 17382520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rectal E. coli above ciprofloxacin ECOFF associate with infectious complications following prostate biopsy.
    Kalalahti I; Huotari K; Lahdensuo K; Tarkka E; Santti H; Rannikko A; Pätäri-Sampo A
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1055-1060. PubMed ID: 29500572
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical consequences of increased ciprofloxacin and gentamicin resistance in patients with Escherichia coli bacteraemia in the Netherlands.
    Cranendonk DR; van der Valk M; Langenberg ML; van der Meer JT
    Scand J Infect Dis; 2012 May; 44(5):363-8. PubMed ID: 22200089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of synergistic interactions of danofloxacin and orbifloxacin against quinolone-resistant Escherichia coli isolated from animals by the checkerboard and time-kill methods.
    Cengiz M; Sahinturk P
    J Antibiot (Tokyo); 2013 Oct; 66(10):629-31. PubMed ID: 23778116
    [No Abstract]   [Full Text] [Related]  

  • 37. Pomegranate pericarp extract enhances the antibacterial activity of ciprofloxacin against extended-spectrum β-lactamase (ESBL) and metallo-β-lactamase (MBL) producing Gram-negative bacilli.
    Dey D; Debnath S; Hazra S; Ghosh S; Ray R; Hazra B
    Food Chem Toxicol; 2012 Dec; 50(12):4302-9. PubMed ID: 22982804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic and genotypic antimicrobial resistance patterns of Escherichia coli isolated from dairy cows with mastitis.
    Srinivasan V; Gillespie BE; Lewis MJ; Nguyen LT; Headrick SI; Schukken YH; Oliver SP
    Vet Microbiol; 2007 Oct; 124(3-4):319-28. PubMed ID: 17544234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance Pattern and Molecular Characterization of Enterotoxigenic Escherichia coli (ETEC) Strains Isolated in Bangladesh.
    Begum YA; Talukder KA; Azmi IJ; Shahnaij M; Sheikh A; Sharmin S; Svennerholm AM; Qadri F
    PLoS One; 2016; 11(7):e0157415. PubMed ID: 27428376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of faecal and optimal growth conditions on in vitro pharmacodynamic activity of marbofloxacin against Escherichia coli.
    Pellet T; Gicquel-Bruneau M; Sanders P; Laurentie M
    Res Vet Sci; 2006 Jun; 80(3):324-35. PubMed ID: 16126240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.